Why AdaptHealth Is Back In Focus
AdaptHealth (AHCO) landed on investor radar after third quarter results paired higher reported sales with a large goodwill impairment charge of $184.75m and a modestly raised full year revenue outlook.
The business also scheduled a presentation at the UBS Global Healthcare Conference on 10 November 2026 in Palm Beach Gardens, Florida, giving management a public forum to explain these updates and address the recent net loss.
AdaptHealth’s share price has moved sharply in recent weeks, with a 30 day share price return of 27.2% and a 90 day gain of 37.0%, yet the year to date share price return is still down 19.2% and the 1 year total shareholder return has declined 16.2%. This signals improving short term momentum against a still weak longer term record and helps explain why the goodwill impairment and raised revenue guidance are getting fresh attention.
Spot fresh momentum stories like AdaptHealth by scanning our hand picked 32 high quality undervalued stocks with resilient balance sheets and cash flows.AdaptHealth has rallied hard off the lows, yet the share price is still down sharply over longer periods. Is this early in a recovery, or has most of the easy upside already played out before valuation even enters the picture?
Most Popular Narrative: 10% Undervalued
At a last close of $7.81, the analyst consensus Narrative on Simply Wall St anchors AdaptHealth’s fair value at $8.71, implying modest undervaluation and putting execution on contracts and cash generation under the microscope.
The large West Coast capitated contract is moving toward the company’s stated margin target, with Q3 2026 margins around 10% and exiting the quarter at roughly 14%. This supports the case that AdaptHealth’s growing capitated book can lift overall EBITDA margins as this and similar contracts mature.
See why 7 investors see AdaptHealth as 10% undervalued.
Result: Fair Value of $8.71 (UNDERVALUED)
Still, the thesis around AdaptHealth can be knocked off course if capitated contracts again run below expected EBITDA contribution, or if supplier pricing changes keep pressuring cash generation.
Find out about the key risks to this AdaptHealth narrative.
Next Steps
If that mix of caution and optimism around AdaptHealth feels familiar, use it as a prompt to move quickly, review the underlying data yourself, and then weigh those 3 key rewards.
Ready To Hunt Beyond AdaptHealth?
If AdaptHealth has sharpened your focus, do not stop here. Use the Simply Wall St Screener to surface fresh ideas before other investors start paying attention.
- Target steadier price action by checking out a curated group of resilient candidates in the 30 resilient stocks with low risk scores.
- Chase value opportunities early by scanning the 19 high quality undiscovered gems that pair stronger fundamentals with quieter market attention.
- Strengthen your core holdings by reviewing a list of solid balance sheet and fundamentals (24 results) that can help anchor a more durable portfolio.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com